Massachusetts General Hospital, Dana Farber Cancer Institute — Boston, Massachusetts

Massachusetts General Hospital, Dana Farber Cancer Institute is a clinical research site located in Boston, Massachusetts, United States 02114.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Massachusetts General Hospital, Dana Farber Cancer Institute has participated in 1 clinical trials.

Therapeutic areas: Advanced Relapsed Tumors, Refractory Solid Tumors.

Sponsors: OncoMed Pharmaceuticals, Inc..

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Massachusetts General Hospital, Dana Farber Cancer Institute?

Massachusetts General Hospital, Dana Farber Cancer Institute has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Massachusetts General Hospital, Dana Farber Cancer Institute conducted?

Massachusetts General Hospital, Dana Farber Cancer Institute has 1 clinical trials on record. Their work covers Advanced Relapsed Tumors, Refractory Solid Tumors.

Is Massachusetts General Hospital, Dana Farber Cancer Institute accredited by Crixeo Health?

Massachusetts General Hospital, Dana Farber Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Massachusetts General Hospital, Dana Farber Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.